在过去的十年中，多种策略彻底改变了皮肤黑色素瘤 (CM) 患者的临床管理，包括免疫疗法和基于靶向酪氨酸激酶抑制剂 (TKI) 的疗法。事实上，免疫检查点抑制剂（ICIs），无论是单独使用还是联合使用，都代表了没有可操作突变的晚期疾病患者的护理标准。值得注意的是，BRAF 与 MEK 抑制剂联合代表了 BRAF 突变疾病的治疗标准。同时，FDG PET/CT已成为皮肤黑色素瘤患者常规分期和评估的一部分。人们对使用 FDG PET/CT 测量来预测 ICI 治疗和/或靶向治疗的反应越来越感兴趣。虽然标准化摄取值（SUV）等半定量值在预测结果方面受到限制，但包括肿瘤代谢体积、总病变糖酵解和放射组学在内的新测量方法似乎有望作为核医学的潜在成像生物标志物。本综述由跨学科专家组编写，其目的是盘点有关可以改善 CM 结果的放射组学方法的最新文献。© 2024。作者。

Over the past decade, several strategies have revolutionized the clinical management of patients with cutaneous melanoma (CM), including immunotherapy and targeted tyrosine kinase inhibitor (TKI)-based therapies. Indeed, immune checkpoint inhibitors (ICIs), alone or in combination, represent the standard of care for patients with advanced disease without an actionable mutation. Notably BRAF combined with MEK inhibitors represent the therapeutic standard for disease disclosing BRAF mutation. At the same time, FDG PET/CT has become part of the routine staging and evaluation of patients with cutaneous melanoma. There is growing interest in using FDG PET/CT measurements to predict response to ICI therapy and/or target therapy. While semiquantitative values such as standardized uptake value (SUV) are limited for predicting outcome, new measures including tumor metabolic volume, total lesion glycolysis and radiomics seem promising as potential imaging biomarkers for nuclear medicine. The aim of this review, prepared by an interdisciplinary group of experts, is to take stock of the current literature on radiomics approaches that could improve outcomes in CM.© 2024. The Author(s).